SEC Form 4	
------------	--

(City)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form filed by More than One Reporting

Person

	0			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	RSHIP	OMB Number: 3235-028 Estimated average burden hours per response: 0.5	
1. Name and Address of Reporting Person* <u>Walker Neal</u> (Last) (First) (Middle) C/O ACLARIS THERAPEUTICS, INC. 101 LINDENWOOD DRIVE, SUITE 400	2. Issuer Name and Ticker or Trading Symbol <u>Aclaris Therapeutics, Inc.</u> [ACRS] 3. Date of Earliest Transaction (Month/Day/Year) 12/15/2016	(Check all applicable X Director X Officer (giv below)	10% Owner	
(Street) ΜΔΙ VERN ΡΔ 19355	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	t/Group Filing (Check Applicable by One Reporting Person	

(State) (Zip)	
---------------	--

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	- Bonnanio G	oounnoo moqu		0.01		- Dome	noidily	ennea		
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)					5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(org.) paro, rananto, oprioritano cocarrico)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock option (right to buy)	\$28.92	12/15/2016		A		145,600		(1)	12/14/2026	Common Stock	145,600	\$0.00	145,600	D	
Restricted stock units	(2)	12/15/2016		Α		24,266		(3)	(3)	Common Stock	24,266	\$0.00	24,266	D	


Explanation of Responses:

1. The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant.

2. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

3. Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone.

Remarks:



12/19/2016

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date